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Abstract
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a malignant liver tumor which is thought to be a variant of
conventional hepatocellular carcinoma (HCC). It accounts for a small proportion of HCC cases and occurs in a
distinctly different group of patients which are young and usually not in the setting of chronic liver disease.
The diagnosis of FL-HCC requires the integration of clinical information, imaging studies, and histology. In terms
of the treatment options, the only potentially curative treatment option for patients who have resectable disease
is surgery either liver resection (LR) or liver transplantation (LT). When performed in a context of aggressive therapy,
long-term outcomes after surgery, particularly liver resection for FL-HCC, were favorable. The clinical outcome of
patients with unresectable disease is suboptimal with median survival of less than 12 months. The aim of this review
is to update the available evidence on diagnosis, treatment options, outcome predictors, and recent developments of
patients with this rare disease and to provide a summarized overview of the available literature.
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Background
Fibrolamellar hepatocellular carcinoma (FL-HCC) is
thought to be a rare variant of conventional hepatocellu-
lar carcinoma (HCC), accounting for 0.85 to 16 % of all
hepatocellular carcinomas [1–7]. It occurs in a distinctly
different group of patients which are young and usually
not in the setting of chronic liver disease (Table 1). The
majority of such cases offer vague and nonspecific clin-
ical symptoms, including weight loss, fatigue, abdominal
pain, and a mass lesion. Alternatively, patients can be
asymptomatic and had their disease discovered inciden-
tally during diagnostic workup of an unrelated medical
condition. Thus, the biological behavior of FL-HCC can
range from an indolent, clinically insignificant disease to
an aggressive pattern of locally invasive disease or dis-
tant metastasis [1, 4, 6, 8–10]. The main goal in the
assessment of patients with FL-HCC is to distinguish FL-
HCC from other malignancies of the liver particularly
HCC and liver metastases and other benign liver lesions
such as focal nodular hyperplasia (FNH) and hepatocellular
adenoma (HCA). This requires the integration of clinical
information with conventional diagnostic techniques such
as ultrasound (US), computed tomography (CT) scans,
magnetic resonance imaging (MRI), and histology. The
only potentially curative treatment option for patients who
have resectable disease is surgery either liver resection (LR)
or liver transplantation (LT). Because it is increasingly safe
and offers a truly curative therapy, liver resection remains
the standard of care for patients with locoregional disease
in a non-cirrhotic liver. When performed in a context of
aggressive therapy, long-term outcomes after surgery, par-
ticularly liver resection for FL-HCC, were favorable. Unfor-
tunately, disease recurrence is high, at 33–100 % [11]. Even
after curative-intent surgery, disease recurrence is frequent,
often in the first 4 years postsurgical [12]. However, it can
also occur after 5 years or even longer [6, 11]. Thus, after
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treatment for FL-HCC, prolonged follow-up is necessary
because recurrence and death can occur years after diagno-
sis. For patients with resectable FL-HCC, 5-year survival
rates as high as 80 % and 5-year disease-free survival rates
of 18 to 50 % have been reported (Table 2). The clinical
outcome of patients with unresectable disease is subopti-
mal with median survival of only 12 months and no patient
surviving beyond 5 years [6, 10]. Furthermore, the role of
neoadjuvant and adjuvant therapies, including systemic
chemotherapy and radiotherapy, remains poorly defined
and has been reported to have only a modest or no thera-
peutic effect [2, 10, 13]. Reports on the characteristics of
patients with FL-HCC as well as predictors of recurrence
and survival are scarce, probably due to the rarity of this
tumor, and are limited to case series, small cohorts, and
few systematic reviews. The aim of this review is to update
the available evidence on diagnosis, treatment options, and
outcome of patients with this rare disease and to provide a
summarized overview of the available literature.
Review
Diagnosis
Clinical finding
Diagnosis of FL-HCC requires consideration of the clinical
conditions, imaging studies, and histologic evaluation.
Patients with FL-HCC are typically young, without under-
lying liver disease, and asymptomatic. Therefore, this tumor
forms a difficult problem in diagnosis. When patients with
FL-HCC are symptomatic, they typically present with non-
specific abdominal pain or discomfort, weight loss, a palp-
able liver mass, ascites, and lower edema [3, 5, 14]. There
may also be a constellation of symptoms, including an-
orexia, fever, and jaundice, and this subject has been re-
cently reviewed by Darcy et al. [15]. These authors reported
that the most common presenting symptom is abdominal
pain (72 %) followed by abdominal distention (44 %), an-
orexia (32 %), fever, and jaundice (20 %). Craig et al. 1980
[8] reported that abdominal pain as the main presenting
symptom is highly variable in duration ranging from 1 to
more than 6 months preceding the diagnosis of FL-HCC.
In general, symptoms are usually present 3 to 12 months
before diagnosis [16].
The routine biochemical and hematological values of
FL-HCC patients are mostly normal or mildly elevated
in a nonspecific fashion [1, 17].
The role of tumor markers
Alpha-fetoprotein (AFP) is the most well-studied serum
marker widely used in diagnostic and screening of HCC.
Unlike HCC, FL-HCC rarely produces AFP. Consequently,
Table 1 Clinicopathologic characteristic of fibrolamellar hepatocellular carcinoma in comparison to conventional hepatocellular carcinoma
Characteristic FL-HCC HCC Comments
Age at presentation Young Older
Sex predilection No 4–8 times more often in men
Distinct geographic
distribution
No Yes HCC is more often seen in Africa
and Asia
Distribution of lesions Mostly solitary Mostly multiple
Growth pattern Indolent Aggressive
Stage at diagnosis Mostly advanced Mostly advanced Despite the advanced stage at
diagnosis, prognosis is in favor
of FL-HCC patients
Chronic viral infection Absent Present
Liver cirrhosis Absent Present Occasionally, underlying liver disease
may be present in patients with
FL-HCC. If present, incidental and not
causative for FL-HCC
α-fetoprotein Within normal range Mostly elevated
Liver resection Treatment of choice Not standard Limited indication in HCC due to
cirrhosis
Liver transplantation Not standard Curative treatment If requirements for LT are fulfilled
Prognosis Favorable Mostly dismal No difference in non-cirrhotic patients
Macro-finding Well-circumscribed, often lobulated
mass, a central gray and white scare
Single or massive, multifocal or nodular,
and diffuse. Due to lack of stroma in the
tumor, often necrosis and hemorrhage
Histology Eosinophilic polygonal-shaped cells
separated by lamellar fibrosis. A fairly
uniform cell pattern. Overall, greater
differentiation than HCC
Thickened plates of hepatocytes with
eosinophilic or clear cytoplasm. Cells are
often arranged in trabecular, pseudoglandular,
or solid pattern
Histologic appearances are the
most objective and widely accepted
differences between FL-HCC and HCC
FL-HCC fibrolamillar hepatocellular carcinoma, HCC conventional hepatocellular carcinoma
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patients with FL-HCC rarely have elevated serum levels
of AFP, and AFP has been demonstrated only in the
minority of patients with FL-HCC in the tumor immu-
nohistochemically [17]. Elevated levels of serum vita-
min B12- and serum unsaturated vitamin B12-binding
capacities have been described as associated with FL-
HCC by some authors [18, 19]. However, additional
evidence and experience are needed to determine the
strength of this association. Elevated serum neuroten-
sin was found to have a role as a biomarker in some
cases, but did not prove to be sensitive or specific
enough for diagnosis [15, 20].
Imaging diagnostic
Imaging of the liver which is an integral part of every
diagnosis is largely performed by cross-sectional imaging
modalities including US, CT, and MRI.
Nuclear medicine studies such as FDG PET can be uti-
lized once a liver lesion is detected and/or there is a
clinical suspicion for extrahepatic manifestation and may
be helpful in narrowing the differential diagnosis. How-
ever, the role of nuclear medicine in the imaging diag-
nostic of FL-HCC has not been fully evaluated [21].
Thus, when a liver mass is detected, characterization can
be performed by several different imaging techniques.
Multiphasic examinations are required with acquisition of
images before and dynamically after the administration of
contrast media to characterize the mass and to determine
the extent of disease. In general, the technique employed
is usually determined by institutional preference and ex-
perience as well as other clinical factors such as patient
history and comorbid conditions such as kidney failure.
US is the initial diagnostic modality for evaluating the
liver. It can detect an intrahepatic mass and intrahepatic
or extrahepatic ductal dilation. However, US is nonspecific
and less accurate than CT or MRI to differentiate FL-HCC
from other mass-forming lesions of the liver. Although CT
is adequate for initial pretreatment imaging of FL-HCC,
particularly for evaluation of metastatic lesions, MRI may
be helpful for initial workup when FL-HCC is first discov-
ered as an initial liver mass [22]. In general, FL-HCC tends
to present as a large, heterogeneous enhancing mass that
may contain a central scar and/or calcifications on im-
aging. Details about imaging findings have been reviewed
extensively in previous publications [14, 16, 21–29] and
summarized in Table 3. Portal vein thrombosis and biliary
Table 2 Summary of clinicopathologic and outcome data of patients with fibrolamellar carcinoma collected from the literature
Author TP YP Total number
of patients
♂:♀ Age CD % AFP↑ LR % LT % 5y-OS %,
LR
5y-OS %,
LT
DR % 5y-DSF % 5y-OS %
Craig et al. [8] 1918–1973 1980 23 1:1 26 None 0/6 48 None nr na nr nr nr (32)
Nagorney et al. [9] 1950–1982 1985 16 1.3:1 26 None 1/6 75 None nr na 75 42 50
Berman et al. [17] 1981–1987 1988 19 2.2:1 25 None 4/15 63 26 nr nr 59 nr nr (37)
Wood et al. [51] 1960–1983 1988 15 1:2.8 26 None 3/9 60 None 45 na nr nr 45 (32)
Iwatsuki et al. [68] 1980–1989 1991 22 nr nr nr nr 55 45 65 38 nr nr nr
Ringe et al. [1] 1974–1988 1992 20 1.2:1 23 None 0/18 70 30 40 (45) nr (29) 60 29 37 (45)
Pinna et al. [2] 1968–1995 1997 41 1.3:1 30 7 2/19 68 32 75 36 66 33 66 (127)
Epstein et al. [30] 1985–1990 1999 17 1:1 24 None 0/16 None None na na nr na nr (14)
El-Gazzaz et al. [3] 1985–1998 2000 20 1:1.9 27 None 0/20 55 45 65 50 45 50 50 (62)
Ichikawa et al. [14] 1989–1997 2000 40 1:1.2 29 None 3/40 62 10 nr nr 71 nr nr
El-Serag and Davila [4] 1986–2000 2004 68 1:1 33 nr nr nr nr nr nr nr nr 37
Kakar et al. [10] 1987–2000 2005 20 1:1 27 None 3/13 nr nr nr nr nr nr 45
Moreno-Luna et al. [5] 1990–2003 2005 15 nr nr nr nr 80 None nr na nr nr 26
Stipa et al. [6] 1986–2003 2006 41 1:1.4 27 None 3/41 68 None 76 na 61 18 76 (112)
Malouf et al. [23] 1987–2007 2012 40 0.3:1 22 3 7/40 100 None 58 na 58 37 58
Mavros et al. [11] 1963–2008 2012 575 1:1.1 21 3 27/266 55 23 70 (222) 34 (32) 33–100 nr 44 (39)
Ang et al. [58] 1986–2011 2013 95 0.7:1 22 nr 3/31 73 4 nr nr 77 nr nr
Kaseb et al. [7] 1992–2008 2013 94 1:1 23 6 13/94 59 2 nr nr 84 nr 46 (57)
Eggert et al. [69] 2000–2010 2013 191 1.7:1 nr nr nr 41 46 58 57 nr nr 34
Groeschl et al. [12] 1993–2010 2014 35 1.7:1 39 14 1/35 100 None 62 na 50 45 62 (174)
Darcy et al. [15] 1981–2011 2015 25 1:1.3 17 None 2/25 84 None 52 na 63 nr 43
TP time period, YP year of publication, ♂:♀ male to female ratio, CD number of patients with chronic liver disease particularly liver cirrhosis in percent of the total
number of patients, AFP↑ number of patients with pathologic elevation of alpha-fetoprotein in relation to tested patients, LR liver resection, LT liver transplant-
ation, 5y-OS 5-year overall survival (numbers in bracket indicate the average survival in months for any treatment), DR disease recurrence, DSF disease free survival,
nr not reported, na not applicable
Kassahun World Journal of Surgical Oncology  (2016) 14:151 Page 3 of 10
obstruction are extremely rare occurring in only 5–10 % of
cases [14, 16, 23, 26, 28]. Nodal metastatic lesions are most
commonly seen at the hepatic hilum and hepatodudenal
ligament occurring in up to 50 to 60 % of cases [6, 14, 21].
Distant metastatic disease from FL-HCC, mostly to the
lungs, peritoneum, and adrenal gland has been reported
on imaging in up to 20–30 % of cases [4, 21, 30].
The role of biopsy
Histologic appearances are the most objective and widely
accepted differences between FL-HCC and HCC [31, 32].
Therefore, histologic confirmation is needed to be able to
diagnose FL-HCC with certainty. This is particularly im-
portant if there is diagnostic uncertainty about the imaging
diagnosis. It enhances the ability to select patients properly
for aggressive surgical intervention by excluding the subset
of patients who do not appear to benefit from surgical
therapy, such as those with extensive metastatic disease or
with underlying medical conditions that preclude surgery.
Fine needle aspiration has low yields and may aspirate ma-
lignant hepatocytes without the characteristic fibrotic la-
mellae resulting in a diagnosis of HCC and not FL-HCC
[33]. Thus, the preferred technique of biopsy is either per-
cutaneous core biopsy or open biopsy via laparoscopy.
Differential diagnosis
The differential diagnosis of FL-HCC includes a wide
spectrum of nonneoplastic and neoplastic lesions of the
liver such as FNH, HCA, and HCC [34]. Differentiation of
other liver lesions from FL-HCC permits optimal patient
treatment. Some of these entities may show characteristic
imaging findings including morphology that permit their
diagnosis (Table 4). However, radiologic findings are gen-
erally inconclusive for a differential diagnosis because the
appearance of the lesions on the various imaging studies
of FL-HCC patients may closely simulate that of FNH,
HCA, HCC, or metastasis [29]. Correlation with clinical
and demographic data may help narrow the differential
diagnosis in patients with FL-HCC. Overall, however, bi-
opsy may be required to achieve definitive histopathologic
characterization in most cases.
Focal nodular hyperplasia
Focal nodular hyperplasia is a hyperplastic nodule that
contains scar-like tissue [35]. It is believed to originate
from hepatocyte proliferation around a congenital ar-
teriovenous malformation and is the second most com-
mon benign hepatic lesion after hemangioma, mostly
seen in women and incidentally detected [36, 37]. Its
growth is may be promoted by oral contraception (OC)
but has no evidenced causal relationship to OC. Because
of macroscopic similarities, common age, and gender to
FL-HCC, FNH is often confused for FL-HCC [33]. Dis-
tinction between these two diagnoses is important be-
cause the clinical approach regarding both is different.
Table 3 Summary of diagnostic imaging findings [14, 16, 22–29, 31]
Diagnostic
imaging
Finding FL-HCC Finding HCC in cirrhosis Comments
US - Well-defined mass of variable
echogenicity
- Partially successful in demonstrating
central scares as a central area of
hyperechogenicity
- Demonstrates calcification within the
fibrous scar
- Lesions may appear hyperechoic,
hypoechoic, or as target lesions,
none of which is specific
- In general, nonspecific sonographic
features
- Less useful for demonstrating necrosis
- Less accurate than CT and MRI in
demonstrating regional lymphadenopathy
- The optimal tool for screening HCC in
cirrhosis
CT - Large tumor with well-defined margins
- Lobulated or smooth surface
- Calcification and a central scare
- Areas of hypervascularity
- Abnormal lymphadenopathy
- Portal vein thrombosis and biliary
obstruction are extremely rare
- Generally tumors show a heterogeneous
hypervascular enhancement
- Necrosis, hemorrhage, focal tumor fat,
and invasion of vascular structures are
common
- Hypoattenuating to surrounding liver
- Central scare, fibrosis, and calcification
are rare
- Arterial hypervascularity (elevated arterial
flow), venous phase washout (reduced or
absent portal venous flow)
- Presence of fat
- In some cases of FL-HCC margins can be
ill defined.
- CT demonstrates calcification in FL-HCC
better than MRI.
- In CT a central scare is not pathognomonic
of FL-HCC
MRI - Large tumor, hypointense on T1-weighted
images and hyperintense on T2-weighted
images
- No calcification but a central scare
- No fat component
- Generally tumors show a heterogeneous
hypervascular enhancement;
hyperattenuating on the arterial phase,
hypo-, iso-, or even hyperattenuating in
venous phases
- Well-circumscribed borders
- Low signal intensity on T1-weighted
images and high signal intensity on
T2-weighted images
- Intratumoral fat
- Tumor encapsulation
- Portal or hepatic vein invasion
- Arterial-portal venous shanting
- Generally, variable in appearance
depending on steatosis or hemorrhage
- MRI is considered to be competitive
rather than complimentary to CT in most
cases.
- MRI demonstrates the central scare in
FL-HCC better than CT
- MRI is may be more sensitive in detecting
small lesions
FL-HCC fibrolamellar hepatocellular carcinoma, HCC, usual hepatocellular carcinoma, US ultrasound, CT computed tomography, MRI magnetic resonance imaging
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While surgery is the treatment option for patients with
FL-HCC, patients with FNH does not require treatment.
Hepatocellular adenoma
Hepatocellular adenoma is a rare benign neoplasm of the
liver that occurs typically in young women of child-bearing
age who have a long history of estrogen-based oral contra-
ceptive use [38, 39]. Owing to hormone-induced growth,
these lesions may rupture and bleed spontaneously leading
to massive hemorrhage [40]. Besides the risk of rupture
and bleeding, about 4.2 % of HCAs have the potential to
undergo malignant transformation into HCC [41]. Thus,
the preferred treatment option is liver resection particu-
larly if lesions are >5 cm in diameter [42]. The diagnosis of
HCA is usually made based on the clinical and imaging
findings and the findings of core biopsies obtained for diag-
nostic workup of a liver mass [33, 43–45]. However, HCA
may sometimes show overlapping diagnostic features with
FL-HCC posing a diagnostic challenge.
Hepatocellular carcinoma
There are major differences in the clinicopathologic
characteristics between conventional HCC and its vari-
ant FL-HCC (Table 1). HCC accounts for significant glo-
bal morbidity and mortality, especially in endemic areas
of chronic viral infection [46]. Contrary to FL-HCC,
HCC has well-defined major risk factors such as chronic
viral infection with hepatitis B and C and aflatoxin B1 in-
take with contaminated food that lead to liver cirrhosis
[47–49]. The majority of cases of HCC develop in liver
cirrhosis, making liver cirrhosis the strongest predisposing
factor [50]. Furthermore, HCC predominantly occurs in
older patients with significant sex predilection (more often
in men over the age of 60), whereas FL-HCC typically af-
fects adolescents and young adults with a nearly even sex
distribution [19, 21].
Surgical treatment
Data in the literature shows that patients with FL-HCC
are good candidates for aggressive surgical treatment;
these patients can expect a reasonable likelihood of dur-
able survival [12]. Liver resection and liver transplantation
are aggressive approaches to the treatment of patients for
FL-HCC and are the only known potentially curative
treatment options for this tumor.
Liver resection
Liver resection is the treatment of choice for FL-HCC
unless it arises in the setting of liver cirrhosis which is
extremely rare. In the absence of liver cirrhosis, patients
with FL-HCC have a high resectability rate (Table 2). As
the majority of FL-HCC patients are young and other-
wise healthy, major liver resection can be done with low
rates of life-threatening complications [46]. Multiple
studies demonstrated OS of 26–76 % at 5 years with a
median survival of 32–174 months for resected patients
[1–3, 6, 7, 11, 12, 51]. Five-year recurrence-free survival
was as low as 18 %; however, even patients in advanced
stage including those with disease recurrence seem to
benefit from aggressive surgery. For example, despite the
fact that 90 % of their patients presented with stage IV
disease, Pinna et al. [2] reported an overall actuarial
Table 4 Clinicopathologic and imaging characteristic of fibrolamillar hepatocellular carcinoma in comparison to focal nodular hyperplasia
and hepatocellular adenoma [21, 35–45, 70–72]
Lesion
Characteristics
FL-HCC FNH HCA
Entity Malignant Benign, mainly proliferating normal
hepatocytes
Benign with the potential to malignant
transformation
Location Anywhere in the liver Frequently in the periphery Anywhere in the liver
Size and number Single, large, and lobulated Single or multiple, small in size Single or multiple, small in size
Sex predilection No Otherwise healthy young women Otherwise healthy young women
Causal relationship to
oral contraception (OC)
Not known Not known Yes
Main findings on
imaging
CT: large tumor, heterogeneous
hypervascular enhancement
MRI: Large tumor, hypointense on
T1-weighted and hyperintense on
T2-weighted images, T2 hypointense
central scare, no fat component,
hyperattenuating on the arterial
phase, hypo-, iso-, or even
hyperattenuating in venous phases
CT: arterial enhancement, presence
of central scare
MRI: arterial enhancement, central
scare predominantly T2 hyperintense,
homogeneous signal intensity,
accumulation of liver-specific contrast
agent within the central area on
delayed T1 images
CT: arterial enhancement, precontrast
hyperdense areas showing hemorrhage,
low-density areas showing necrosis or fat
MRI: arterial enhancement, hyperintense
areas on T1, T2 images showing
hemorrhage, hypointense areas on T1
that correlate to hyperintense areas on
T2 images showing necrosis, no
accumulation of liver-specific contrast
agent within the lesion
Treatment Surgical Normally requires no treatment Discontinuation of OC, surgical
FL-HCC fibrolamellar hepatocellular carcinoma, FNH focal nodular hyperplasia, HCA hepatocellular adenoma, CT computed tomography, MRI magnetic
resonance imaging
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survival of 66 % at 5 years and 47 % at 10 years. Accord-
ing to these authors, this survival advantage was attrib-
uted to indolent growth, favorable biological behavior,
and suitability to extensive liver resection including adja-
cent structures initially as well as to treat recurrence.
Disease recurrence after complete surgical resection
is high in this patient population ranging 33–100 %
[1–3, 7, 9, 11–15]. The median time to recurrence is rela-
tively short at between 10 and 33 months [1, 3, 6, 13, 14].
However, recurrence of disease more than 5 years after
surgery is a rare event [2, 12]. The high recurrence rate
after surgery may seem somewhat surprising, especially
given that patients were treated aggressively and at highly
specialized hepatobiliary centers. However, quite often pa-
tients with FL-HCC are referred to these centers at an ad-
vanced stage, with large primary tumors and evidence of
lymph node metastases, both factors which has been iden-
tified as negative prognostic indicators [2, 3, 6, 12, 13, 15].
Furthermore, for those patients with recurrence after
liver transplantation, in addition to advanced tumor
stage, the issue of immunosuppression should also be
considered because it may significantly increase the re-
currence rate [52].
Repeat surgery has been considered by many to be the
most effective treatment for recurrence [6–8, 12]. Re-
resection aimed at recurrent or metastatic disease, when
possible, may provide patients with good long-term re-
sults. For example, in a study of Stipa et al. [6], 28 patients
with FL-HCC underwent LR with an overall recurrence
rate of 61 %. The mean time to recurrence was 37 months.
Recurrence was exclusively intrahepatic in approximately
half of the 17 patients with disease recurrence. Despite
this high recurrence rate, all patients were amenable to
treatment with re-resection that resulted in median sur-
vival of 26 months. In the study of Kaseb et al. [7], metas-
tasectomy was done in 18 cases and was found to be
significantly associated with longer OS. The median OS
was 145 months for those who underwent surgery versus
35 months for those who did not. In the study of Maniaci
et al. [13] that included 10 patients, disease recurrence oc-
curred in all patients following initial surgery with a me-
dian time to recurrence of 2.2 years. In seven patients,
disease recurrence was managed surgically that resulted in
a median survival of 4.7 years and an OS of 48 % at 5 years.
Therefore, as such, tumor recurrence should not preclude
resection when complete removal can be achieved because
it carries a relatively good prognosis. Patient selection and
an emphasis on surgical technique to achieve complete re-
moval are pivotal to optimizing the best chance for the
best possible outcome.
Liver transplantation
LT is an effective treatment for HCC, and its indications
are expanding [53]. On the contrary, only FL-HCC which
is not amenable to resection but confined to the liver is
considered a suitable indication for LT by the majority of
investigators [2, 3, 11]. Thus, the use of LT for advanced
disease is unique to FL-HCC. However, owing to its rarity
and the infrequent need for LT, available data is limited.
Theoretically, LT has the potential to readily achieve a
clean margin, accomplish a radical removal of the tumor,
and treat underlying liver disease when present. In 1997,
Pinna et al. [2] examined the results of 13 patients who
underwent LT for FL-HCC. The overall 3- and 5-year sur-
vival rates were 45 and 36 %, respectively. However, dis-
ease recurrence was confirmed in 9 (69 %) out of 13
Patients. These authors analyzed the specific factors that
might serve as predictors of disease recurrence after LT.
Patients with regional lymph node involvement (N1),
those with the presence of metastasis (M1), and those with
stage IVB disease were more likely to develop recurrent
disease. Interestingly, the use of chemotherapy in an adju-
vant setting was also associated with earlier intrahepatic
recurrence.
In a series which included nine patients with FL-HCC
treated by LT, El-Gazzaz et al. [3] reported 1-, 3-, and 5-
year survival rates of 90, 75, and 50 %, respectively. Disease
recurrence occurred in five (56 %) out of nine transplanted
patients. Two of the nine transplanted patients received
chemotherapy in neoadjuvant and adjuvant setting, and
chemotherapy had no detectable effect on survival or
recurrence-free survival.
In a systematic review published in 2012, Mavros et al.
[11] reported the results of 14 studies that included 109
patients after LT for FL-HCC. Six studies reported specific
survival data on 79 patients. Survival after 1, 3, and 5 years
ranged from 63 to 100 %, 43 to 75 %, and 29 to 55 %.
In a meta-analysis of 17 studies involving 368 pa-
tients with FL-HCC and 9877 patients with conven-
tional HCC, Njei et al. [54] found significantly higher
5-year survival rates in those patients with FL-HCC
treated by LR than did those with conventional HCC.
But, they found no difference in survival in patients
undergoing liver transplantation.
Overall, patients who underwent LR for FL-HCC did
better than patients who underwent LT. However, with
the number of published trials increasing, the aggregate
data indicated acceptable outcomes for patients who
underwent LT as well. Thus, given the advanced stage of
disease in transplanted patients, LT for FL-HCC does not
appear to be an inferior treatment option in comparison
with LR and may have more indications than the current
standard of care. However, given the rarity of the disease
and the retrospective nature of data collection from differ-
ent institutions with a very small sample size, most pub-
lished series lack sufficient power for statistical analysis
and the results are inconclusive. Thus, the perception of
good survival outcomes after LT despite the advanced
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stage of disease is probably inaccurate and should there-
fore be interpreted with caution.
Chemotherapy
The role of neoadjuvant or adjuvant chemotherapy is con-
troversial. In some cases, chemotherapy had no effect on
survival or recurrence in patients who received chemo-
therapy after surgery [2, 3]. Contrary to this, in other stud-
ies, patients who had chemotherapy in neoadjuvant and
adjuvant settings fared better than those with surgery only
with patients who had front-line surgery followed by
chemotherapy having the longest OS [7, 55]. In one report
[56], the use of platinum-based chemotherapy in pediatric
patients with FL-HCC resulted a partial response in 31 %
of patients on imaging but a 3-year survival of only 22 %.
Thus, although some different types of systemic chemo-
therapy for FL-HCC have been tried, the advances in
tumor downstaging with this therapeutic option have not
proven effective. The most difficult aspect of understand-
ing the utility of chemotherapy for FL-HCC is that no pro-
spective trials have investigated different types of
chemotherapy options. Instead, most knowledge about the
effectiveness of chemotherapy is based on anecdotal evi-
dence and single-patient experience.
Outcome and prognostic factors
Although FL-HCC patients often present with an ad-
vanced disease, approximately 50–84 % of affected pa-
tients are amenable to surgical treatment and have an
OS as high as 76 % at 5 years (Table 2). Thus, patients
with FL-HCC appear to have a better prognosis than
those with HCC which have a far worse prognosis with a
5-year survival of only 6.8 % [4]. However, considering
similar stage disease, patients with FL-HCC do not have
a favorable prognosis and do not respond any differently
to treatment than patients with HCC in non-cirrhotic
livers [9, 10, 51, 54, 57]. This suggests that the apparent
better outcome seen in FL-HCC may be related to the
absence of liver cirrhosis. Thus, as indicated by some of
the reviewed studies, along with the indolent nature of
the disease and younger age, the most likely reason for
this favorable outcome is the absence of liver cirrhosis
that allows aggressive surgical treatment [4, 6, 8, 10, 17].
Individual tumor stage, number and size of tumors, vas-
cular invasion, regional lymph node metastasis, the pres-
ence of extrahepatic disease, non-White race, and female
gender have been thought to be negative predictors of
outcome after surgery [1, 2, 6, 10, 12, 15, 58]. Of these,
the initial stage of the tumor at the time of treatment
seems to be the most significant determinant of progno-
sis. Patients with stage I–III disease tended to fare better
than patients with stage IV disease [1, 2, 6, 23], and in
some cases, this difference attains statistical significance
[2, 12, 23]. Overall, however, additional studies with
large number of patients are needed, since the existing
data does not result in a differentiation firm enough to
base treatment decisions on.
Recent developments
Currently, researchers are attempting to provide some in-
sights into the molecular characteristics of FL-HCC. Using
genomic analysis, some patterns of genomic aberrations
which are different from other liver malignancies have
been shown and possible pathways and candidate genes as
therapeutic targets have been identified. However, these
discoveries of molecular pathways and genetic mutations
that characterize FL-HCC have not yet enhanced the abil-
ity to design specific anticancer therapies.
DNAJB1-PRKACA: this recently described predomin-
ant fusion protein has been proved to retain the kinase
activity of PRKACA, the catalytic subunit of protein kin-
ase A (PKA) [59–61]. DNAJB1-PRKACA may represent
a potential therapeutic target as high levels of DNAJB1-
PRKACA protein expression (amplified in more than
70 % of FL-HCC) have been found in FL-HCC com-
pared to a normal liver or HCC [59]. Because of the
many oncogenic signaling pathways regulated by PKA
[62, 63], kinase inhibitors which bind near the active site
of the PKA catalytic subunit can target several onco-
genic proteins in parallel [64]. Currently, however, no
known drug trials are using such inhibitors specifically
against FL-HCC.
mTOR: the mammalian target of rapamycin (mTOR)
is an intracellular protein kinase (PK) expressed in mam-
malian cells and is critical in the development of many
malignant tumors [65]. The mTOR pathway is respon-
sible for regulating cell growth and survival. It mediates
signaling transduction downstream of receptor tyrosine
kinases. If this pathway becomes dysfunctional, mTOR
becomes upregulated, leading to increased cell prolifera-
tion, angiogenesis, and evasion of apoptosis [66]. Conse-
quently, inhibitors of this pathway have been assessed
and evaluated for their safety and efficacy in cancer pa-
tients. For example, the mTOR inhibitor everolimus in
combination with octereotide has been shown to be ef-
fective for low- and intermediate-grade neuroendocrine
tumors. Most patients experienced either a partial re-
sponse or stable disease, with a minority experiencing
tumor progression [67].
Anticancer agents that induce durable remissions are
needed particularly for those FL-HCC patients whose tu-
mors are not amenable to aggressive surgery. Currently,
it has been shown that mTOR signaling significantly ac-
tivated in FL-HCC compared to other liver malignancies
[61]. This suggests that mTOR inhibitors may have anti-
cancer activity in FL-HCC as well. Recently, however,
there have been no published trials using mTOR inhibi-
tors that target its dysregulated pathways for patients
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diagnosed with FL-HCC. Thus, given the present results in
drug research regarding the treatment of FL-HCC, it is
highly unlikely that a marked prolongation of life in pa-
tients with advanced FL-HCC is on the immediate horizon.
Conclusions
A familiarity with the diagnosis, treatment, and overall
management of FL-HCC is necessary for all those dealing
with these patients. The optimal approach to management
involves accurate diagnosis and staging, followed by as-
sessment of candidacy for liver resection or transplant-
ation. The diagnosis of FL-HCC is often difficult, and it
requires careful assessment of the clinical findings and
multiple, complimentary, imaging modalities and biopsy.
Liver resection is the preferred treatment option; however,
in selected patients, liver transplantation can also be con-
sidered as an option. With few presented conflicting re-
sults of retrospective studies, the role of other therapeutic
options such as chemotherapy is controversial. For now, it
seems that these options are uniformly ineffective in
prolonging survival. The resistance of FL-HCC to these
treatment options likely contributes to poor outcomes in
patients presenting with extensive metastatic disease. Sur-
gery for recurrent disease, even when present with re-
gional metastases, can achieve a meaningful survival
benefit. Thus, surveillance must be maintained, even be-
yond 5 years. The more indolent course of this tumor and
its good response to aggressive surgical therapy suggest
that future research and treatment strategy should be de-
signed in a manner that addresses more appropriately the
treatment of patients who have tumors that may be less
sensitive and not amenable to surgical therapy. Because of
its very low incidence, research on targeted therapy is dif-
ficult and has not yet been successful. Therefore, national
and international collaborations are required to achieve
this objective.
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